An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
Status:
Terminated
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to find out if paclitaxel works better when given together with
an experimental drug called MORAb-003 (farletuzumab) or alone in patients with
platinum-resistant or refractory relapsed ovarian cancer